Last 48 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
TherapeuticsMD, Inc.'s quarterly P/E stands at 61.6x.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -39.63 | 61.59 | — | 20.61 | 6.09 | — | 9.82 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 7.47 | 8.12 | 5.28 | 3.99 | 3.53 | 6.80 | 3.72 | 8.75 | 19.84 | 21.09 | 12.92 | — | 24.09 |
| — | +19.4% | +42.0% | -54.4% | -82.2% | -67.8% | -71.2% | — | -17.6% | -4.0% | +13.7% | — | +2952.8% | |
| P/B Ratio | 0.84 | 0.87 | 0.70 | 0.46 | 0.49 | 0.40 | 0.36 | 0.71 | 0.67 | 0.92 | 0.89 | 1.15 | 1.35 |
| — | +118.1% | +93.6% | -35.5% | -26.7% | -56.6% | -59.1% | -38.7% | -50.3% | -19.3% | -40.5% | — | — | |
| P/FCF | 9.31 | 6.28 | 12.81 | 2.99 | 10.36 | 3.89 | 206.62 | — | 5.19 | 600.19 | — | — | — |
| — | +61.3% | -93.8% | — | +99.5% | -99.4% | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 55.98 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
TherapeuticsMD, Inc.'s operating margin was -99.9% in Q1 2026, up 67.7 pp QoQ and up 121.8 pp YoY. The trailing four-quarter average of -111.6% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 44.9% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 55.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -26.9% | 100.0% | 100.0% |
| — | -44.9% | 0.0% | 0.0% | 0.0% | 0.0% | +471.9% | 0.0% | 0.0% | 0.0% | +86.4% | +22.1% | +19.9% | |
| Operating Margin | -139.4% | -99.9% | -167.5% | -105.9% | -73.0% | -221.6% | -47.8% | -157.0% | -1191.9% | -364.9% | -320.9% | 3345.3% | -565.7% |
| — | +54.9% | -250.3% | +32.6% | +93.9% | +39.3% | +85.1% | -104.7% | -110.7% | +43.1% | -103.3% | +3472.7% | -757.5% | |
| Net Margin | -18.8% | 13.1% | -69.3% | 19.4% | 57.9% | -166.2% | 37.8% | -111.3% | -465.8% | -234.5% | -175.9% | 6373.6% | -552.4% |
| — | +107.9% | -283.5% | +117.4% | +112.4% | +29.1% | +121.5% | -101.7% | +15.7% | +72.9% | +93.9% | +4702.7% | -240.5% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -2.1% | 0.4% | -2.3% | 0.6% | 2.0% | -2.4% | 0.9% | -2.2% | -3.9% | -2.5% | -3.1% | -11.4% | -7.6% |
| — | +114.6% | -346.3% | +125.0% | +152.7% | +4.7% | +130.0% | +80.5% | +49.3% | +76.4% | +96.7% | — | — | |
| ROA | -1.5% | 0.3% | -1.6% | 0.4% | 1.4% | -1.7% | 0.6% | -1.5% | -2.7% | -1.7% | -1.9% | -6.5% | -4.3% |
| — | +114.9% | -352.2% | +125.8% | +154.2% | +1.4% | +134.2% | +76.4% | +37.8% | +64.2% | +93.6% | +68.6% | -105.3% | |
| ROIC | -11.7% | -2.3% | -4.4% | -2.3% | -1.9% | -2.3% | -0.8% | -2.2% | -6.7% | -2.6% | -4.1% | -5.1% | -7.5% |
| — | +0.4% | -438.5% | -5.2% | +72.2% | +13.6% | +80.2% | +57.7% | +10.7% | +80.8% | -100.8% | +87.7% | +76.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 17.8% YoY to 3.11x, strengthening the short-term liquidity position. Debt/Equity has declined for 8 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.18 | 0.19 | 0.24 | 0.24 | 0.26 | 0.26 | 0.27 | 0.27 | 0.27 | 0.27 | 0.29 | 0.27 |
| — | -31.4% | -27.3% | -13.5% | -11.8% | -4.2% | -4.1% | -6.6% | +2.1% | +1.6% | +9.7% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.02 | 3.11 | 3.02 | 2.46 | 2.89 | 2.64 | 1.92 | 2.03 | 2.03 | 1.42 | 1.72 | 1.20 | 1.20 |
| — | +17.8% | +57.1% | +21.0% | +42.0% | +85.8% | +11.6% | +69.2% | +69.0% | +11.1% | +45.6% | +139.2% | +100.1% | |
| Quick Ratio | 3.02 | 3.11 | 3.02 | 2.46 | 2.89 | 2.64 | 1.92 | 2.03 | 2.06 | 1.42 | 1.72 | 1.20 | 1.20 |
| — | +17.8% | +57.1% | +21.0% | +40.0% | +85.8% | +11.6% | +69.2% | +71.4% | +11.1% | +45.6% | +159.0% | +113.4% | |
| Interest Coverage | — | — | — | 17.67 | -159.50 | -391.50 | — | -286.33 | -235.80 | — | -17.64 | -70.70 | -52.64 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TXMD stock.
TherapeuticsMD, Inc.'s current P/E is -39.6x. The average P/E over the last 3 quarters is 29.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
TherapeuticsMD, Inc.'s current operating margin is -139.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking TherapeuticsMD, Inc.'s business trajectory between earnings reports.